UK markets close in 1 hour 37 minutes

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.04-0.48 (-1.13%)
As of 09:52AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 5.17B
Enterprise value 4.95B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.82
Price/book (mrq)19.37
Enterprise value/revenue 9.44
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.96
52-week change 3-51.66%
S&P500 52-week change 326.43%
52-week high 394.75
52-week low 319.83
50-day moving average 353.98
200-day moving average 351.33

Share statistics

Avg vol (3-month) 31.45M
Avg vol (10-day) 32.33M
Shares outstanding 5121.37M
Implied shares outstanding 6121.37M
Float 881.88M
% held by insiders 114.30%
% held by institutions 196.21%
Shares short (15 Apr 2024) 410.67M
Short ratio (15 Apr 2024) 49.39
Short % of float (15 Apr 2024) 412.16%
Short % of shares outstanding (15 Apr 2024) 48.80%
Shares short (prior month 15 Mar 2024) 410.59M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -79.62%
Operating margin (ttm)-36.03%

Management effectiveness

Return on assets (ttm)-27.90%
Return on equity (ttm)-122.94%

Income statement

Revenue (ttm)524.07M
Revenue per share (ttm)4.33
Quarterly revenue growth (yoy)284.30%
Gross profit (ttm)N/A
EBITDA -402.32M
Net income avi to common (ttm)-417.27M
Diluted EPS (ttm)-3.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)333.54M
Total cash per share (mrq)2.75
Total debt (mrq)109.14M
Total debt/equity (mrq)40.92%
Current ratio (mrq)3.77
Book value per share (mrq)2.20

Cash flow statement

Operating cash flow (ttm)-550.1M
Levered free cash flow (ttm)-383.48M